Acute chest pain (ACP) remains a common, yet challenging, clinical presentation. Its etiology ranges from benign conditions to life-threatening emergencies, making its evaluation critical. This article presents a comprehensive approach to diagnosing and managing ACP in clinical practice.
ACP evaluation begins with a thorough history and physical examination to identify high-risk features. Vital signs, patient's age, comorbidities, and the nature of the pain are crucial in this assessment. The HEART score, a validated tool, can guide risk stratification and further management.
Electrocardiogram (ECG) is the initial diagnostic test, with the potential to identify ST-elevation myocardial infarction (STEMI). If ECG is non-diagnostic, biomarkers such as Troponin can aid in the diagnosis. However, a negative initial biomarker does not rule out acute coronary syndrome (ACS). Additional testing such as stress testing or coronary angiography may be warranted based on risk stratification.
Management of ACP is guided by the likely etiology. For suspected ACS, early reperfusion therapy is crucial. High-risk patients may benefit from early invasive strategies. Conversely, low-risk patients may be managed conservatively. Non-cardiac causes of ACP should also be considered and managed accordingly.
Clinical Decision Units (CDUs) have emerged as a valuable resource for managing patients with ACP. They provide a setting for continued observation, further testing, and decision-making. CDUs have been shown to reduce hospital admissions and healthcare costs without compromising patient outcomes.
Diagnosing and managing ACP requires a systematic approach, combining clinical assessment, risk stratification, diagnostic testing, and appropriate management strategies. The use of CDUs can optimize this process, improving patient outcomes while reducing healthcare costs. As our understanding of ACP evolves, so too must our approach to its evaluation and management.
1.
Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months
2.
A study on lung cancer provides additional proof of the value of screening.
3.
Medical Journal March 29, 2023
4.
Thriving while surviving: Understanding the social needs of cancer survivors
5.
Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth
1.
The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers
2.
Personalized Survivorship Navigation in Precision Cancer Care
3.
Personalized Tumor Ecological Landscapes in Oncology
4.
Integrated Frameworks in Hematology in Clinical Decision-Making
5.
Immune Surveillance Screening for Early Cancer Risk Detection
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
2.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
5.
How Cancer Screening Supports Early Diagnosis
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation